Contract 75A50119C00037
Emergent Biosolutions Canada Inc · Department Of Health And Human Services · June 30, 2025
Emergent Biosolutions Canada Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on June 30, 2025 for $105.65 million of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 2 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 23, 2026. If all options are exercised, the contract could reach $706.47 million.
Contract details
- PIID
- 75A50119C00037
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Not Competed
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- June 30, 2025
- Latest action
- March 23, 2026
Description
VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATES SERVICES FOR UP TO 10 YEARS.
Modification timeline
-
March 23, 2026Mod P00017 · Exercise An Option$422.32M
-
July 2, 2025Mod P00016 · Exercise An Option$368.58M
-
June 30, 2025Mod P00015 · Change OrderVACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS.$316.67M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | Department Of Health And Human Services | March 31, 2026 | $122.8K |
| Four Points Technology, L.L.C. | Department Of Health And Human Services | March 31, 2026 | $246.6K |
| Ase Direct, Inc. | Department Of Health And Human Services | March 30, 2026 | $49.0K |
| Emergent Biosolutions Canada Inc | Department Of Health And Human Services | March 30, 2026 | $256.40M |
| Mckesson Corporation | Department Of Health And Human Services | March 30, 2026 | $9.00M |
| Sanofi Vaccines Us Inc. | Department Of Health And Human Services | March 27, 2026 | $92.33M |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50119C00037?
Contract 75A50119C00037 is a federal contract awarded to Emergent Biosolutions Canada Inc by Department Of Health And Human Services on June 30, 2025 for $105.65 million of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 2 times since the base award.
Who won contract 75A50119C00037?
Emergent Biosolutions Canada Inc won contract 75A50119C00037 from Department Of Health And Human Services.
How much is contract 75A50119C00037 worth?
Contract 75A50119C00037 has obligated $105.65 million to date, with a total potential value of $706.47 million if all options are exercised.